نبذة مختصرة : Background: Reduction of immunosuppression (IS) upon detection of Polyomavirus (BK) viremia is widely used to prevent BK virus nephropathy. This retrospective case-control study assesses the frequency of de novo donor-specific antibodies (dnDSA) in renal transplant recipients with IS modulation due to BK viremia and the associated risk of antibody mediated rejection.
Methods: Our cohort included recipients of kidney transplantation between 2007 and 2017 with clinical, HLA antibody, and biopsy data. BK positivity was defined as viremia >10 000 c/ml or biopsy proven BK nephropathy. A total of 190 BK cases matched our inclusion criteria, each case was matched with two controls based on gender, donor type, and transplant within 1 year (N = 396).
Results: Despite lower number of HLA antigen mismatches (mean = 3.5 vs. 4.4, p < .001), dnDSA rates were higher in BK cases than in control group (22.1% vs. 13.9%, p = .02), with the majority detected following IS reduction for BK infection, and arising earlier posttransplant compared with no BK infection (294d vs. 434d, p < .001). Antibody mediated rejection rates were similar between cases and controls (8.9% and 8.3%, respectively), but rejection was more likely to occur earlier posttransplant in the BK cases (354d vs. 602d, p = .03).
Conclusion: Our data suggest a link between IS reduction and the generation of dnDSA and/or rejection, supporting close monitoring for DSA in patients with reduced IS due to BK infection given their increased risk to develop dnDSA.
(© 2022 Wiley Periodicals LLC.)
References: Almeras C, Vetromile F, Garrigue C, et al. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. Transpl Infect Dis. 2011;13(2):101-108.
Hirsch HH, Knowles W, Dickenmann C, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347(7):488-496.
Koukoulaki M, Grispou E, Pistolas D, et al. Prospective monitoring of BK virus replication in renal transplant recipients. Transpl Infect Dis. 2009;11(1):1-10.
Bicalho CS, Oliveira RDR, David DR, et al. Determination of viremia cut-off for risk to develop BKPyV-associated nephropathy among kidney transplant recipients. Transpl Infect Dis. 2018;20(5):e12969.
Hirsch HH, Randhawa PS, AST Infectious Diseases Community of Practice, BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13528.
Randhawa P, Ho A, Shapiro R, et al. Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J Clin Microbiol. 2004;42(3):1176-1180.
Bischof N, Hirsch HH, Wehmeier C, et al. Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes. Nephrol Dial Transplant. 2019;34(7):1240-1250.
Cheungpasitporn W, Kremers WK, Lorenz E, et al. De novo donor-specific antibody following BK nephropathy: the incidence and association with antibody-mediated rejection. Clin Transplant. 2018;32(3):e13194.
Dieplinger G, Everly MJ, Brilet KP, et al. Onset and progression of de novo donor-specific anti-human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction. Transpl Infect Dis. 2015;17(6):848-858.
Hardinger KL, Koch MJ, Bohl DJ, et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant. 2010;10(2):407-415.
Sawinski D, Forde KA, Trofe-Clark J, et al. Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies. J Am Soc Nephrol. 2015;26(4):966-975.
Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant. 2010;10(12):2615-2623.
Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am J Transplant. 2005;5(10):2539-2548.
Theodoropoulos N, Wang E, Penugonda S, et al. BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation. Am J Transplant. 2013;13(1):197-206.
Echterdiek F, Latus J, Dohler B, et al. Impact of HLA compatibility in recipients of kidneys from expanded criteria donors: a collaborative transplant study report. Int J Immunogenet. 2021;48(2):201-210.
Williams RC, Gerhard O, Jennifer WE, et al. The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors. Transplantation. 2016;100(5):1094-1102.
Williams RC, Gerhard O, Jennifer WE, et al. The risk of transplant failure with HLA mismatch in first adult kidney allografts 2: living donors, summary, guide. Transplant Direct. 2017;3(5):e152.
Zachary AA, Leffell MS, HLA mismatching strategies for solid organ transplantation - a balancing act. Front Immunol. 2016;7:575.
Patel SJ, Kuten SA, Knight RJ, et al. Incidence and factors associated with de novo DSA after BK viremia in renal transplant recipients. Clin Transpl. 2016;32:103-109.
Pinelli DF, Zachary AA, Friedewald JJ, et al. Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy. Am J Transplant. 2019;19(2):381-390.
Devresse A, Tinel C, Vermorel A, et al. No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained BK virus viremia after kidney transplantation: a single-center experience. Transpl Int. 2019;32(5):481-492.
Heidt S, Feltkamp MC, Karahan GE, et al. No evidence for cross-reactivity of virus-specific antibodies with HLA alloantigens. Transplantation. 2018;102(11):1844-1849.
Aiello FB, Calabrese F, Rigotti P, et al. Acute rejection and graft survival in renal transplanted patients with viral diseases. Mod Pathol. 2004;17(2):189-196.
Yard B, Spruyt-Gerritse M, Claas F, et al. The clinical significance of allospecific antibodies against endothelial cells detected with an antibody-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation. Transplantation. 1993;55(6):1287-1293.
Bishop GA, Hall BM, Suranyi MG, et al. Expression of HLA antigens on renal tubular cells in culture. I. Evidence that mixed lymphocyte culture supernatants and gamma interferon increase both class I and class II HLA antigens. Transplantation. 1986;42(6):671-679.
Processing Request
No Comments.